Takeda has undergone a transformation in the 6 years since Christophe Weber was named CEO. Buyouts helped build the company into a top 15 R&D player, with global commercial and research capabilities. Now that the pandemic has begun to wane, what is Weber planning for the next 6 years as Takeda takes its place among the global giants?
A year ago we invited a group of top R&D chiefs to discuss the impact the pandemic had on the field. Now we’re following up the discussion by concentrating on the new normal era ahead. What’s changed forever for R&D groups? What’s the central focus on the FDA front now and where are the greatest organizational challenges going forward as major organizations adapt to a new way of doing business with digital endpoints and more.
The global pandemic has a long way to run globally. While the US outbreak may be on the verge of being contained, new variants and a multitude of pipeline problems is keeping this issue alive. As a result, we’ve already seen a host of followup drugs and vaccines enter human testing, and we’ll see lots more in the months ahead. We’ll talk to some of the leaders in the field, and get a better idea of how this can develop in late 2021 and throughout 2022.
The Covid-19 pandemic has challenged an increasingly global pharmaceutical supply chain as drugmakers have had to weather the storm of periodic lockdowns, chronic shortages and major delays at the FDA. Now, with the first phase of the pandemic over but variants still on the loose, what will the industry choose — whether practical or philosophical — to take away from the lockdown days? Our group of experts will share their thoughts on the new normal in manufacturing and when the industry expects to get running at full speed again.
Unexpectedly, Joe Biden barreled into the White House with a busy agenda, ramping up new regulations and laying out new policies that could have a major impact on the biopharma industry. Pricing, the regulatory environment at the FDA and FTC, and economic policy have all been pushed to the forefront. Let’s unpack what’s happening and what you should be watching out for.
As a scientist and an entrepreneur Robert Langer has helped launch more than 30 biotechs exploring a multitude of therapeutic arenas over the years — often involving his grad students. He helped found Moderna, which went on to trigger a revolution in vaccine development. And he continues to have his thumb on both the scientific and business side of the industry. We’ll be discussing both as Langer looks back — and forward.